海藻酸钾

海藻酸钾试食组主要临床症状积分降低，与安慰剂对照组及试食前比较差异有统计学意义（P0.05）。

The main clinical symptom score in Potassium alginate group was significantly lower than that before the test and that in control group ( P 0.05 ) .

低分子海藻酸钾降压作用及药动学的实验研究

Antihypertensive Effect and Pharmacokinetics of Low Molecular Mass Potassium Alginate

结论海藻酸钾散剂与寿比山具有相似的降压疗效，是一种安全、有效的降压药。

Conclusion The efficacy and safety of potassium alginate for hypertension was similar to indapamide .

海藻酸钾试食组试食期间静息心率与试食前比较有所下降，但与安慰剂对照组相应时点静息心率比较差异无统计学意义。

The resting heart rate of patients in Potassium alginate group descended significantly compared with that detected before the test , but no significant difference was observed when it compared with that in placebo control group .